62. 発作性夜間ヘモグロビン尿症 Disease details / Clinical trials / Drug dev / DR info

ABP 959   
   Amgen
      2019   Phase 3   NCT03818607   Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
ABP 959 - biosimilar to eculizumab   
   Amgen Inc.
      2020   Phase 3   EUCTR2017-001418-27-PT   Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001418-27-IE   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001418-27-FI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-SI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-NO   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-NL   Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom;
      2019   Phase 3   EUCTR2017-001418-27-DE   Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-CZ   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001418-27-GB   Germany;Italy;Netherlands;Norway;Spain;United Kingdom;
      2017   Phase 3   EUCTR2017-001418-27-ES   France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;
ABP 959 - proposed biosimilar to eculizumab   
   Amgen Inc.
      2020   Phase 3   EUCTR2017-001418-27-SE   Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
ACH-0144471   
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2016-002652-25-IT   Italy;Korea, Republic of;New Zealand;United Kingdom;
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-003829-18-IT   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
   Achillion Pharmaceuticals, Inc.
      2018   Phase 2   EUCTR2017-000665-79-GB   Italy;Korea, Republic of;New Zealand;United Kingdom;
      2018   Phase 2   EUCTR2016-002652-25-GB   Italy;Korea, Republic of;New Zealand;United Kingdom;
   Alexion Pharmaceuticals
      2018   Phase 2   NCT03472885   United States;
      2017   Phase 2   NCT03181633   Italy;Korea, Republic of;New Zealand;
      2017   Phase 2   NCT03053102   Italy;Korea, Republic of;New Zealand;United Kingdom;
   Alexion Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2019-003829-18-PL   Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003829-18-NL   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003829-18-GB   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003829-18-FR   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
ACH-0145228   
   Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-IT   Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003830-17-GB   Italy;Korea, Republic of;New Zealand;United Kingdom;United States;
   Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-ES   Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;
ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
ALN-62643   
   Alnylam Pharmaceuticals Inc
      2016   Phase 2   EUCTR2016-002943-40-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;
ALN-CC5   
   Alnylam Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02352493   Spain;United Kingdom;
   Alnylam Pharmaceuticals Inc
      2016   Phase 2   EUCTR2016-002943-40-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Netherlands;Norway;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;
   Regeneron Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
ALXN1102   
   Alexion Pharmaceuticals
      2011   Phase 1   NCT01335165   Czech Republic;Italy;Poland;United Kingdom;United States;
ALXN1103   
   Alexion Pharmaceuticals
      2011   Phase 1   NCT01335165   Czech Republic;Italy;Poland;United Kingdom;United States;
ALXN1210   
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2017-002370-39-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-IT   Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   Alexion Pharmaceuticals
      2018   Phase 3   NCT03406507   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2015   Phase 1/Phase 2   NCT02598583   Australia;Korea, Republic of;
   Alexion Pharmaceuticals Inc.
      2020   Phase 4   EUCTR2019-003440-74-GB   United Kingdom;
   Alexion Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002820-26-NO   France;Netherlands;Norway;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002820-26-NL   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002820-26-GB   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States;
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-PL   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002820-26-FR   France;Netherlands;United States;
   Alexion Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-002370-39-SE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-FI   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002370-39-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002674-20-SE   Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;
      2015   Phase 2   EUCTR2015-002674-20-GB   Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002674-20-DE   Canada;Finland;France;Germany;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
      2015   -   EUCTR2015-002674-20-ES   Canada;Finland;France;Germany;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;
ALXN2040   
   Alexion Pharmaceuticals Inc.
      2022   Phase 3   EUCTR2019-003829-18-GR   Argentina;Brazil;Canada;Colombia;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003829-18-DE   Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
ALXN2040 (ACH-0144471)   
   Alexion Pharmaceuticals Inc.
      2018   Phase 2   EUCTR2016-003526-16-GB   Italy;United Kingdom;United States;
ALXN2050   
   Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-IT   Italy;Korea, Republic of;New Zealand;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003830-17-GB   Italy;Korea, Republic of;New Zealand;United Kingdom;United States;
   Alexion Pharmaceuticals
      2019   Phase 2   NCT04170023   Canada;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;United States;
   Alexion Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2019-003830-17-ES   Canada;France;Germany;Italy;Korea, Republic of;New Zealand;Spain;Turkey;United Kingdom;
APL-2   
   Apellis Pharmaceuticals
      2018   Phase 2   EUCTR2017-005140-16-GR   Bulgaria;Greece;Poland;Romania;Serbia;
      2018   Phase 2   EUCTR2017-005140-16-BG   Bulgaria;Greece;Poland;Romania;Serbia;
   Apellis Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001106-23-FR   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001106-23-ES   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   NCT04085601   Colombia;Hong Kong;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Singapore;Thailand;
      2019   Phase 3   EUCTR2018-004220-11-PL   Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand;
      2019   Phase 3   EUCTR2017-004268-36-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004268-36-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   NCT03500549   Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004268-36-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004268-36-ES   Australia;Canada;Japan;Korea, Republic of;Russian Federation;Spain;United States;
      2018   Phase 3   EUCTR2017-004268-36-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004268-36-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 2   NCT03593200   Bulgaria;Greece;Poland;Romania;Serbia;
      2015   Phase 1   NCT02588833   Hong Kong;Malaysia;New Zealand;Thailand;
      2015   Phase 1   NCT02264639   United States;
ARO-C3   
   Arrowhead Pharmaceuticals
      2022   Phase 1   NCT05083364   New Zealand;
Allogeneic Bone Marrow Transplantation   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Allogeneic hematopoietic stem cell transplantation   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2009   -   NCT00856388   United States;
Allogeneic stem cell transplantation   
   St. Jude Children's Research Hospital
      2005   Phase 2   NCT00143559   United States;
Anti-C5 antibody   
   ALEXION PHARMACEUTICALS INCORPORATED
      2006   -   EUCTR2005-000043-28-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-000043-28-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002795-42-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002795-42-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002795-42-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-000043-28-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-000043-28-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002795-42-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002795-42-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2004   Phase 3   EUCTR2004-000646-20-IE   Ireland;Italy;Sweden;United Kingdom;
      2004   Phase 3   EUCTR2004-000646-20-GB   Ireland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000646-20-SE   Ireland;Italy;Sweden;
   ALEXION PHARMACEUTICALS, INC.
      -   -   EUCTR2009-010402-11-Outside-EU/EEA   United States;
Anti-thymocyte globulin   
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States;
BCD-148   
   Biocad
      2019   Phase 3   NCT04060264   Russian Federation;
BCX9930   
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116774   France;Hungary;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 2   NCT04702568   Austria;South Africa;United Kingdom;
      2020   Phase 1/Phase 2   NCT04330534   Austria;South Africa;United Kingdom;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004403-14-LT   Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Lithuania;Serbia;South Africa;Turkey;United States;
      2021   Phase 2   EUCTR2020-004403-14-ES   Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Lithuania;Serbia;South Africa;Spain;Turkey;United States;
BCX9930 hydrochloride   
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004403-14-IT   Albania;Argentina;Azerbaijan;Brazil;Canada;China;European Union;Italy;Lithuania;Serbia;South Africa;Spain;Turkey;United States;
      2020   Phase 2   EUCTR2020-000501-93-IT   Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-000501-93-GB   European Union;South Africa;United Kingdom;
      2020   Phase 2   EUCTR2020-000501-93-DK   Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
      2020   Phase 2   EUCTR2020-000501-93-AT   Austria;Denmark;European Union;Italy;South Africa;United Kingdom;
BCX9930 monotherapy   
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116787   Malaysia;South Africa;Spain;Taiwan;United States;
BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
BEXSERO – Sospensione iniettabile – Siringa preriempita   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
Bryostatin 1   
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00012376   United States;
C5 Inhibitor   
   Alexion Pharmaceuticals
      2020   Phase 3   NCT04469465   Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Thailand;United Kingdom;United States;
C5 inh MAb, SKY59, RO/CH7092230   
   F. HOFFMANN - LA ROCHE LTD.
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-IT   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-HU   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-FR   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
      2016   Phase 1;Phase 2   EUCTR2016-002128-10-NL   Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom;
COVERSIN   
   Akari Therapeutics Plc
      2019   Phase 3   EUCTR2016-004129-18-LT   Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Campath, Chemo and/or TBI Allo SCT   
   David Rizzieri, MD
      1999   Phase 2   NCT00004143   United States;
Cemdisiran   
   Regeneron Pharmaceuticals
      2022   Phase 3   NCT05133531   United States;
      2021   Phase 2   NCT04888507   United Kingdom;
      2021   Phase 2   NCT04811716   Hungary;Korea, Republic of;
Crovalimab   
   CHUGAI PHARMACEUTICAL CO., LTD.
      2017   Phase 1-2   JPRN-JapicCTI-173517   Japan, Asia except Japan, Europe;
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205430   Japan, Asia except Japan, North America, South America, Europe, Oceania;
      2020   Phase 3   JPRN-JapicCTI-205425   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000597-26-IT   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Hoffmann-La Roche
      2021   Phase 3   NCT04654468   China;
      2020   Phase 3   NCT04434092   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04432584   Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 1/Phase 2   NCT03157635   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
Cyclophosphamide   
   National Heart, Lung, and Blood Institute (NHLBI)
      2019   Phase 2   NCT03520647   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      1996   Phase 2   NCT00004464   United States;
Cyclosporine   
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States;
Cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant   
   Memorial Sloan Kettering Cancer Center
      2001   Phase 2   NCT00587054   United States;
Danicopan   
   Alexion Pharmaceuticals
      2020   Phase 3   NCT04469465   Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Thailand;United Kingdom;United States;
   Alexion Pharmaceuticals Inc.
      2018   Phase 2   EUCTR2016-003526-16-GB   Italy;United Kingdom;United States;
   Kamata Takeo
      2021   Phase 3   JPRN-jRCT2021210014   America;Japan;
Danicopan (ALXN2040)   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-003829-18-IT   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
   Alexion Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2019-003829-18-PL   Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Taiwan;Thailand;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003829-18-NL   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003829-18-GB   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003829-18-FR   Australia;Austria;Brazil;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;Thailand;United Kingdom;United States;
Eculizumab   
   ALEXION PHARMACEUTICALS INC
      2005   -   EUCTR2005-000043-28-IT   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002795-42-IT   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-000646-20-IT   Ireland;Italy;Sweden;
   ALEXION PHARMACEUTICALS INCORPORATED
      2006   -   EUCTR2005-000043-28-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2005-000043-28-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002795-42-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002795-42-GB   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-002795-42-ES   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-000043-28-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-000043-28-IE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002795-42-SE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002795-42-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
      2004   Phase 3   EUCTR2004-000646-20-IE   Ireland;Italy;Sweden;United Kingdom;
      2004   Phase 3   EUCTR2004-000646-20-GB   Ireland;Italy;Sweden;United Kingdom;
      2004   -   EUCTR2004-000646-20-SE   Ireland;Italy;Sweden;
   Alexion Pharmaceuticals
      2021   Phase 4   NCT04320602   United Kingdom;
      2018   Phase 2   NCT03472885   United States;
      2017   Phase 3   NCT03056040   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   NCT02946463   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2009   Phase 4   NCT00867932   United States;
      2008   Phase 2   NCT01194804   -
      2007   Phase 3   NCT00438789   United States;
      2007   Phase 2   NCT01192399   -
      2005   Phase 3   NCT00122317   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2004   Phase 3   NCT00122330   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States;
      2004   Phase 3   NCT00122304   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
   Amgen
      2019   Phase 3   NCT03818607   Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116774   France;Hungary;Spain;Taiwan;United Kingdom;United States;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
   Chugai Pharmaceutical Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205430   Japan, Asia except Japan, North America, South America, Europe, Oceania;
      2020   Phase 3   JPRN-JapicCTI-205425   Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000597-26-IT   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Hoffmann-La Roche
      2020   Phase 3   NCT04434092   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04432584   Australia;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Singapore;Slovakia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Jonsson Comprehensive Cancer Center
      2004   Phase 3   NCT00112983   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 3   NCT00130000   United States;
      2004   Phase 3   NCT00098280   United States;
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04558918   Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Radboud University
      2021   -   NCT04079257   Netherlands;
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2051200132   Japan;Netherlands;
Elizaria®   
   AO GENERIUM
      2019   -   NCT04671810   Russian Federation;
      2017   Phase 3   NCT04463056   Russian Federation;
Fc- and CDR-modified humanised monoclonal antibody against C5   
   Alexion Pharmaceuticals Incorporated
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States;
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-PL   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Alexion Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-002370-39-SE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-FI   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002370-39-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
Filgrastim   
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      1996   Phase 2   NCT00004464   United States;
Fludarabine Phosphate   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Fludarabine phosphate   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2009   -   NCT00856388   United States;
G-CSF   
   Tianjin Medical University General Hospital
      2014   -   ChiCTR-ONC-13003994   China;
Gelatin   
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2021210059   Italy;Japan;Republic of Korea;Taiwan;
H5G1.1-mAb   
   ALEXION PHARMACEUTICALS INC
      2005   -   EUCTR2005-000043-28-IT   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
HAEMOPHILUS INFLUENZAE   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
Human monoclonal antibody directed against complement 5 protein   
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania;
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania;
Iptacopan   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2021   Phase 3   EUCTR2020-004385-19-ES   Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States;
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-004385-19-NL   Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-004385-19-LT   Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-004385-19-FR   Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-003172-41-FR   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003172-41-CZ   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania;
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania;
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04747613   France;Italy;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;
Iptacopan (LNP023)   
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04820530   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;
Iron Dextran   
   Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
      2014   -   ChiCTR-TRC-14004219   China;
Iron sucrose   
   Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences
      2014   -   ChiCTR-TRC-14004219   China;
L04AA25   
   ALEXION PHARMACEUTICALS INCORPORATED
      2005   -   EUCTR2005-000043-28-DE   Germany;Ireland;Italy;Spain;Sweden;United Kingdom;
LFG316   
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania;
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania;
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02534909   Czech Republic;Czechia;Japan;Lithuania;Moldova, Republic of;
LNP023   
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04558918   Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 2   NCT03896152   Korea, Republic of;Malaysia;Russian Federation;Singapore;Taiwan;
      2018   Phase 2   NCT03439839   France;Germany;Italy;
LNP023 HYDROCHLORIDE SALT   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Levamisole+cyclosporin A+Glucocorticoids   
   Institute of Hematology & Blood Diseases Hospital
      2013   Phase 2   NCT01760096   China;
      2012   Phase 2   NCT01642979   China;
MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
MENVEO – Polvere e soluzione per soluzione iniettabile   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Melphalan   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2009   -   NCT00856388   United States;
Methotrexate   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Methylprednisolone   
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2021   Phase 2   ChiCTR2000039675   Chinese;
Miltenyi Biotec CliniMACS   
   St. Jude Children's Research Hospital
      2003   Phase 2   NCT00145613   United States;
Miltenyi CliniMACS   
   St. Jude Children's Research Hospital
      2005   Phase 2   NCT00143559   United States;
Mycophenolate mofetil   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Myeloablative Preparative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
No   
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania;
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States;
PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Pegcetacoplan   
   Apellis Pharmaceuticals, Inc.
      2021   Phase 2   NCT04901936   United States;
      2021   -   NCT04729062   United States;
      2020   Phase 3   EUCTR2019-001106-23-FR   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001106-23-ES   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001106-23-BG   Australia;Bulgaria;Canada;France;Germany;Hong Kong;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004220-11-PL   Argentina;Brazil;Colombia;Hong Kong;Hungary;Malaysia;Mexico;Peru;Philippines;Poland;Serbia;Thailand;
      2018   Phase 3   NCT03531255   Australia;Belgium;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Singapore;Spain;Thailand;United Kingdom;United States;
      -   Phase 2   EUCTR2020-001350-21-CZ   Australia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Malaysia;Netherlands;Poland;Romania;Serbia;Spain;Thailand;United Kingdom;United States;
Pegcetacoplan (APL-2)   
   Apellis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2019-001106-23-GB   Australia;Bulgaria;Canada;France;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004268-36-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001106-23-DE   Australia;Bulgaria;Canada;France;Germany;Hong Kong;Japan;Korea, Republic of;Malaysia;Russian Federation;Serbia;Spain;Thailand;United Kingdom;United States;
Peripheral Blood Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
      2006   Phase 2   NCT00397813   Denmark;Germany;Italy;United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
Peripheral blood stem cell transplantation   
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Pozelimab   
   Regeneron Pharmaceuticals
      2022   Phase 3   NCT05133531   United States;
      2021   Phase 2   NCT04888507   United Kingdom;
      2021   Phase 2   NCT04811716   Hungary;Korea, Republic of;
   Regeneron Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
RA101495   
   Ra Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-003956-19-FI   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003523-34-FI   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
RA101495 sodium   
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003523-34-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003523-34-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003522-16-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
      2017   Phase 2   EUCTR2016-003522-16-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
      2017   Phase 2   EUCTR2016-003522-16-FI   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
      2017   Phase 2   EUCTR2016-003522-16-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
REGN3918   
   REGENERON PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2019-000130-20-IT   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002734-20-IT   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
   Regeneron Pharmaceuticals
      2019   Phase 3   NCT04162470   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
      2019   Phase 2   NCT03946748   Hong Kong;Hungary;Korea, Republic of;Malaysia;United Kingdom;
   Regeneron Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-005005-17-HU   Hong Kong;Hungary;Korea, Republic of;Malaysia;Taiwan;United Kingdom;
      2020   Phase 3   EUCTR2019-000130-20-NL   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000130-20-HU   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000130-20-GB   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000130-20-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-002734-20-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002734-20-NL   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002734-20-HU   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002734-20-GB   Canada;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Malaysia;Netherlands;Poland;Romania;Singapore;South Africa;Taiwan;United Kingdom;United States;
RO7112689   
   CHUGAI PHARMACEUTICAL CO., LTD.
      2017   Phase 1-2   JPRN-JapicCTI-173517   Japan, Asia except Japan, Europe;
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000597-26-IT   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-FR   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-HU   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-PT   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000597-26-CZ   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000597-26-PL   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000597-26-GR   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RO7112689/F01   
   F. HOFFMANN - LA ROCHE LTD.
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-IT   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-HU   Brazil;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-FR   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
      2016   Phase 1;Phase 2   EUCTR2016-002128-10-NL   Brazil;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;United Kingdom;
RO7112689/F03-01   
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RO7112689/F03-03   
   F. Hoffmann-La Roche Ltd
      2017   Phase 1;Phase 2   EUCTR2016-002128-10-DE   France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;
RO7112689/F03-10   
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004931-21-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
RVA576   
   AKARI Therapeutics
      2018   Phase 3   NCT03588026   Kazakhstan;Lithuania;Sri Lanka;
   Akari Therapeutics Plc
      2019   Phase 3   EUCTR2016-004129-18-LT   Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
      2018   Phase 3   EUCTR2016-004129-18-NL   Argentina;Lithuania;Netherlands;Poland;United Kingdom;
      2017   Phase 3   EUCTR2016-004129-18-GB   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
      2016   Phase 2   EUCTR2016-002067-33-GB   United Kingdom;
   Akari Therapeutics Plc.
      2018   Phase 3   EUCTR2017-003847-39-LT   Ecuador;Kazakhstan;Lithuania;Peru;Romania;Sri Lanka;Turkey;
   Volution Immuno Pharmaceuticals (UK) Ltd
      2016   Phase 2   EUCTR2015-003778-34-NL   Netherlands;
RVA576 (COVERSIN)   
   Akari Therapeutics Plc
      2017   Phase 3   EUCTR2016-004129-18-PL   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
RVA576 (Coversin)   
   AKARI Therapeutics
      2017   Phase 3   NCT03829449   Poland;
   Akari Therapeutics Plc
      2017   Phase 3   EUCTR2016-004129-18-PL   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Ravulizumab   
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2017-002370-39-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   Alexion Pharmaceuticals
      2022   -   NCT05274633   -
      2021   Phase 4   NCT04320602   United Kingdom;
      2017   Phase 3   NCT03056040   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 3   NCT02946463   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Estonia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 2   NCT02605993   Canada;France;Germany;Korea, Republic of;Spain;Sweden;Taiwan;United Kingdom;
   Alexion Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002820-26-NL   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002820-26-GB   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Netherlands;Spain;United Kingdom;United States;
   Alexion Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-002370-39-SE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-GB   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-FI   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-ES   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-DE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-CZ   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-BE   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002370-39-AT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002370-39-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Finland;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States;
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05116774   France;Hungary;Spain;Taiwan;United Kingdom;United States;
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04558918   Brazil;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Regeneron Pharmaceuticals
      2022   Phase 3   NCT05133531   United States;
   Suzuki Kazuyuki
      2021   Phase 3   JPRN-jRCT2051200132   Japan;Netherlands;
Reduced Intensity Preparative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
Reduced Toxicity Ablative Regimen   
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States;
SB12 (proposed eculizumab biosimilar)   
   Samsung Bioepis Co., Ltd.
      2019   Phase 3   NCT04058158   India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine;
SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)   
   ALEXION PHARMACEUTICALS INCORPORATED
      2017   Phase 3   EUCTR2016-002026-36-IT   Germany;Italy;Netherlands;Spain;United Kingdom;United States;
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
SOLIRIS® (eculizumab) injection, for intravenous use   
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-PT   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Sargramostim   
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00012376   United States;
Sirolimus   
   Peking Union Medical College Hospital
      2019   Phase 4   NCT03866681   China;
Solaris   
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Soliris   
   ALEXION PHARMACEUTICALS INCORPORATED
      2017   Phase 3   EUCTR2016-002025-11-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   Alexion Pharmaceuticals Incorporated
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-GB   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-ES   Germany;Spain;United States;
      2017   Phase 3   EUCTR2016-002026-36-DE   Australia;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-PT   Austria;Denmark;Estonia;Germany;Korea, Republic of;Poland;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-PL   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-ES   Austria;Denmark;Germany;Korea, Republic of;Spain;United States;
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
      2017   Phase 3   EUCTR2016-002025-11-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Korea, Republic of;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2016-002025-11-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Amgen Inc.
      2020   Phase 3   EUCTR2017-001418-27-SE   Brazil;Czech Republic;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001418-27-PT   Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001418-27-IE   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001418-27-FI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-SI   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-NO   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-NL   Germany;Italy;Korea, Republic of;Netherlands;Norway;Spain;United Kingdom;
      2019   Phase 3   EUCTR2017-001418-27-DE   Czech Republic;France;Germany;Ireland;Italy;Netherlands;Norway;Slovenia;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-001418-27-CZ   Brazil;Czech Republic;Czechia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Portugal;Slovenia;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-001418-27-GB   Germany;Italy;Netherlands;Norway;Spain;United Kingdom;
      2017   Phase 3   EUCTR2017-001418-27-ES   France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;
   Apellis Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2017-004268-36-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004268-36-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004268-36-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   NCT03500549   Australia;Belgium;Canada;France;Germany;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004268-36-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004268-36-ES   Australia;Canada;Japan;Korea, Republic of;Russian Federation;Spain;United States;
      2018   Phase 3   EUCTR2017-004268-36-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004268-36-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
   Biocad
      2019   Phase 3   NCT04060264   Russian Federation;
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2019-004931-21-IT   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-FR   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004931-21-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-PL   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-HU   Argentina;Australia;Belgium;Brazil;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004931-21-DE   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004931-21-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000597-26-EE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000597-26-BE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000597-26-DE   Australia;Belgium;Brazil;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000597-26-SE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-000597-26-IE   Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Philippines;Poland;Portugal;Romania;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
   NOVARTIS PHARMA AG
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-FR   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Soliris (eculizumab)   
   Samsung Bioepis Co., Ltd.
      2019   Phase 3   NCT04058158   India;Korea, Republic of;Malaysia;Mexico;Romania;Taiwan;Thailand;Ukraine;
Soliris 300   
   Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd
      2019   Phase 4   EUCTR2019-001453-10-ES   Argentina;Brazil;Canada;Colombia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Romania;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
Soliris 300 mg concentrate for solution for infusion   
   F. Hoffman-La Roche Ltd.
      2021   Phase 3   EUCTR2019-004931-21-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czechia;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Soliris 300mg/30ml   
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Soliris®   
   AO GENERIUM
      2017   Phase 3   NCT04463056   Russian Federation;
Stem Cell Transplantation   
   St. Jude Children's Research Hospital
      2003   Phase 2   NCT00145613   United States;
Sterile Normal Saline ( NaCl)   
   Alnylam Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02352493   Spain;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide   
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003522-16-FI   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24   
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003523-34-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003523-34-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003522-16-HU   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
      2017   Phase 2   EUCTR2016-003522-16-GB   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
      2017   Phase 2   EUCTR2016-003522-16-DK   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker   
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-FI   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker   
   Ra Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-003956-19-FI   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Georgia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Spain;Taiwan;Turkey;United Kingdom;United States;
Systematic chemotherapy and antibodies   
   St. Jude Children's Research Hospital
      2005   Phase 2   NCT00143559   United States;
Systemic chemotherapy and antibodies   
   St. Jude Children's Research Hospital
      2003   Phase 2   NCT00145613   United States;
Tacrolimus   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
Treosulfan   
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Tretinoin   
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2021   Phase 2   ChiCTR2000039675   Chinese;
ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO   
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-004438-39-IT   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
Ultomiris   
   Alexion Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002820-26-NL   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002820-26-GB   France;Netherlands;Norway;Russian Federation;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002026-36-NL   Germany;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002025-11-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States Minor Outlying Islands;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004438-39-HU   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Italy;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-FR   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004438-39-ES   Argentina;Brazil;Canada;China;Colombia;European Union;France;Hungary;Japan;Korea, Republic of;Spain;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
Ultomiris 300mg/30ml   
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
VACCINO PNEUMOCOCCICO   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004385-19-IT   Brazil;China;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-003172-41-IT   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-IT   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
VARI   
   ALEXION PHARMACEUTICALS INC
      2004   -   EUCTR2004-000646-20-IT   Ireland;Italy;Sweden;
Zilucoplan   
   Ra Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2016-003523-34-FI   Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
Zilucoplan (RA101495)   
   Ra Pharmaceuticals
      2017   Phase 2   NCT03225287   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;United States;
      2017   Phase 2   NCT03078582   Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom;
      2017   Phase 2   NCT03030183   United States;
 LNP023 HYDROCHLORIDE SALT   
   Novartis Farmacéutica, S.A.
      2021   Phase 3   EUCTR2020-004385-19-ES   Brazil;China;Japan;Korea, Republic of;Malaysia;Singapore;Spain;Taiwan;United States;
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-004385-19-NL   Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-004385-19-LT   Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-004385-19-FR   Brazil;China;France;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Singapore;Spain;Taiwan;United States;
      2021   Phase 3   EUCTR2020-003172-41-FR   China;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003172-41-CZ   China;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Singapore;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004665-40-DE   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004665-40-CZ   Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-NL   Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-HU   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004665-40-FR   Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000888-33-FR   France;Germany;Italy;
      2018   Phase 2   EUCTR2017-000888-33-DE   France;Germany;Italy;
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2014-005338-74-LT   Czech Republic;Czechia;Japan;Lithuania;
      2015   Phase 2   EUCTR2014-005338-74-CZ   Czech Republic;Czechia;Japan;Lithuania;